{"product_id":"tuxiflud-scir-15mg-5ml","title":"TUXIFLUD*SCIR 15MG\/5ML","description":"\u003cp\u003e\u003cb\u003eTuxiflud 3 mg\/ml Syrup - 150 ml bottle\u003cbr\u003e Tuxiflud 0.75% Nebuliser Solution - 40 ml bottle\u003cbr\u003e Tuxiflud 15 mg\/2 ml Nebuliser Solution - 15 single-dose containers\u003cbr\u003e Tuxiflud 15 mg\/2 ml nebuliser solution - 6 x 2 ml ampoules\u003c\/b\u003e\u003cbr\u003e Equivalent medicine\u003c\/p\u003e\u003cp\u003e\u003cb\u003eWhat it is and what it is used for\u003c\/b\u003e\u003cbr\u003eTreatment of secretion disorders in acute and chronic bronchopulmonary conditions.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eWhat you need to know before taking the medicine\u003c\/b\u003e\u003cbr\u003eHypersensitivity to the active substance or to any of the excipients.\u003cbr\u003e Severe liver and\/or kidney impairment.\u003cbr\u003e Tuxiflud “3 mg\/ml Syrup” is contraindicated in children under 2 years of age.\u003c\/p\u003e\u003cp\u003e\u003cb\u003eWarnings and precautions\u003c\/b\u003e\u003cbr\u003eMucolytics can cause bronchial obstruction in children under 2 years of age. This is because the ability to drain bronchial mucus is limited in this age group, due to the physiological characteristics of the respiratory tract. They should therefore not be used in children under 2 years of age (for the syrup).\u003cbr\u003e \u003cbr\u003e Tuxiflud should be administered with caution in patients with peptic ulcers.\u003cbr\u003e Tuxiflud 0.75% nebuliser solution in a 40 ml bottle contains benzalkonium chloride as a preservative. Especially when the medicine is used for long periods, benzalkonium chloride can cause swelling of the nasal mucosa. If such a reaction (persistent nasal congestion) is suspected, a nasal medicine without BAC should be used if possible. If such nasal medicines without BAC are not available, another pharmaceutical form should be considered. Furthermore, benzalkonium chloride can cause bronchospasm.\u003cbr\u003e \u003cbr\u003e Cases of severe skin reactions associated with Ambroxol administration have been reported.\u003cbr\u003e If you develop a skin rash (including lesions of mucous membranes such as the mouth, throat, nose, eyes, genitals), stop taking Ambroxol and contact your doctor immediately.\u003cbr\u003e \u003cbr\u003e Tuxiflud in the 15 mg\/2ml nebuliser solution 15 single-dose containers and 3 mg\/ml syrup packs contain: \u003cb\u003emethyl parahydroxybenzoate\u003c\/b\u003e and \u003cb\u003epropyl parahydroxybenzoate:\u003c\/b\u003e mild irritants to skin, eyes and mucous membranes. They may increase the risk of jaundice in newborns.\u003cbr\u003e \u003cbr\u003e \u003cem\u003e\u003cb\u003ePregnancy and breastfeeding\u003c\/b\u003e\u003c\/em\u003e\u003cbr\u003e During pregnancy and breastfeeding, ambroxol should only be used after consulting your doctor and evaluating the risk\/benefit ratio in your case.\u003cbr\u003e Consult your doctor if you suspect you are pregnant or wish to plan a pregnancy.\u003cbr\u003e There are no clinical data on exposed pregnancies for ambroxol.\u003cbr\u003e Animal studies do not indicate direct or indirect harmful effects on pregnancy, embryonic\/foetal development, birth or post-natal development. Caution should be exercised when prescribing the medicine to pregnant women. During pregnancy, medicines should only be used if the expected benefit to the mother is considered greater than the risk to the foetus. All medicines should be avoided, if possible, during the first trimester of pregnancy. The medicine is secreted into breast milk.\u003cbr\u003e The use of ambroxol by the mother can cause undesirable effects in the infant; therefore, it is necessary to decide whether to stop breastfeeding or treatment with the medicine, taking into consideration the importance of the medicine for the mother.\u003c\/p\u003e\u003cp\u003e\u003cb\u003ePossible side effects\u003c\/b\u003e\u003cbr\u003eRarely: tiredness, dry mouth, rhinorrhoea, dysuria, headache, gastrointestinal disorders (heartburn, dyspepsia, constipation, nausea and vomiting), contact dermatitis or other allergic reactions (especially skin rashes).\u003cbr\u003e \u003cbr\u003e \u003cu\u003eRare: may affect up to 1 in 1000 people:\u003c\/u\u003e\u003cbr\u003e Hypersensitivity reactions\u003cbr\u003e Rash, urticaria\u003cbr\u003e \u003cbr\u003e \u003cu\u003eNot known: frequency cannot be defined based on available data\u003c\/u\u003e\u003cbr\u003e \u003cbr\u003e Anaphylactic reactions, including anaphylactic shock, angioedema (rapidly developing swelling of the skin, subcutaneous tissues, mucosa and submucosal tissues) and itching.\u003cbr\u003e \u003cbr\u003e Severe cutaneous adverse reactions (including erythema multiforme, Stevens-Johnson syndrome\/toxic epidermal necrolysis and acute generalised exanthematous pustulosis).\u003cbr\u003e \u003cbr\u003e \u003cb\u003eReporting of side effects\u003c\/b\u003e\u003cbr\u003e If you get any side effects, including those not listed in this leaflet, talk to your doctor or pharmacist. You can also report side effects directly via the national reporting system at: \u003cu\u003ehttps:\/\/www.aifa.gov.it\/content\/segnalazionireazioni-avverse\u003c\/u\u003e.\u003cbr\u003e By reporting side effects, you can help provide more information on the safety of this medicine.\u003c\/p\u003e\u003cp\u003e\u003ca href=\"https:\/\/www.salute.gov.it\/portale\/temi\/soggettoAutorizzatoVenditaOnlineFarmaciMDS.jsp?VOLID=F14409%20\" target=\"_blank\"\u003e\u003cimg src=\"https:\/\/www.farmania.it\/farmaco\/farmaco-promo-farmacia.png\"\u003e\u003c\/a\u003e\u003c\/p\u003e","brand":"DYMALIFE PHARMACEUTICAL Srl","offers":[{"title":"Default Title","offer_id":52818615992587,"sku":"035128014","price":11.15,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/farmaonline24.it\/en\/products\/tuxiflud-scir-15mg-5ml","provider":"FarmaOnline24","version":"1.0","type":"link"}